ArticleBJU international2025
Men's experiences of the Swedish Organised Prostate Cancer Testing programme: a qualitative study.
Article in BJU international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mapping the readiness landscape for prostate cancer screening in Europe: analysis of health system capacity across the PRAISE-U pilots.EClinicalMedicine · 2026Article
- Prostate specific antigen retesting intervals and trends in England: population based cohort study.BMJ (Clinical research ed.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo investigate men's experiences of undergoing the diagnostic pathway within the Swedish Organised Prostate Cancer Testing (OPT) programme in Stockholm County. SUBJECTS AND
methodsThe OPT in Sweden is a structured programme aimed at reducing unnecessary medical interventions while ensuring early detection. Men in selected age groups receive an invitation, including information on the benefits and risks of prostate-specific antigen (PSA) testing. Those with PSA levels above a pre-defined threshold (≥3 ng/mL) are referred for magnetic resonance imaging (MRI) to assess the need for further evaluation. If MRI indicates a biopsy is needed, men are referred to urology for targeted and/or systematic biopsy. To explore men's experiences with the diagnostic pathway of the OPT, semi-structured interviews were conducted with 22 participants in Stockholm County. Thematic analysis was used to identify, analyse, and describe patterns within the data.
resultsAfter their initial PSA test, informants expressed a need for more guidance in interpreting their test results. At the MRI stage, they requested clearer information, as it requires preparations that could otherwise be overlooked. For the biopsy, informants desired more support before and after the procedure, as it can trigger fear and anxiety. Overall, they perceived the diagnostic pathway as efficient but too automated. They requested more personalised information and support, especially towards the end of the process.
conclusionThis study shows that the OPT programme was well received by participating men; however, they requested more personalised information and support throughout the process. These needs increased further along the diagnostic pathway as the examinations became more invasive and the risk of detecting prostate cancer increased. Patient perspectives need to be considered to improve this programme and similar programmes in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.